| |
Total cohort n (%)
|
fPSM n (%)
|
ePSM n (%)
|
p
|
|---|
|
Patients (n)
|
189
|
115 (60.9)
|
74 (39.1)
| |
|
Mean age (standard deviation)
|
71.8 (+/−6.3)
|
70.3 (+/−7.5)
|
74.1 (+/−8.3)
|
0.006
|
|
Mean PSA (standard deviation)
|
8.8 (+/−4.3)
|
8.1 (+/−3.6)
|
10.0 (+/−4.9)
|
0.003
|
|
Gleason Score (pG)
| | | |
0.14
|
|
≤ 6
|
63 (33.3)
|
43 (37.4)
|
20 (27)
|
|
7
|
119 (63)
|
68 (59.1)
|
51 (68.9)
|
|
3 + 4
|
96 (49.2)
|
57 (49.6)
|
36 (48.6)
|
|
4 + 3
|
23 (13.8)
|
11 (9.6)
|
15 (20.3)
|
|
≥8
|
7 (3.7)
|
4 (3.5)
|
3 (4)
|
|
pT Stage
| | | |
0.61
|
|
T2a
|
15 (7.9)
|
9 (7.8)
|
6 (8.1)
|
|
T2b
|
24 (12.7)
|
16 (13.9)
|
8 (10.8)
|
|
T2c
|
101 (53.4)
|
64 (55.6)
|
37 (50)
|
|
T3a
|
49 (25.9)
|
26 (22.6)
|
23 (31.1)
|
|
Median follow-up (months)
|
101.1
|
95.3
|
110.3
|
0.08
|
- fPSM focal positive surgical margin, ePSM extensive positive surgical margin, PSA prostate-specific antigen
